Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

Journal of the American Academy of Dermatology
Volume 41, n° 6
pages 987-990 (décembre 1999)
Doi : 10.1016/S0190-9622(99)70258-6
Side-controlled intradermal injection of botulinum toxin A in recalcitrant axillary hyperhidrosis

Marc Heckmann, MD a, Susanne Breit, MD a, Andres Ceballos-Baumann, MD b, Martin Schaller, MD a, Gerd Plewig, MD a
a Department of Dermatology, Ludwig-Maximilians-Universität Munich, Germany 
b Department of Neurology, Technische Universität. Munich, Germany 


Background: Although topical application of aluminium chloride is the most common measure against axillary sweating, severely affected patients often undergo surgical procedures that are expensive and may have considerable side effects. Recently botulinum toxin A (BT-A) has been reported as a potentially effective antihyperhidrotic agent. Objective: Our purpose was to determine the therapeutic strength, safety, and mode of application of BT-A in severe axillary hyperhidrosis. Methods: Intradermal injection of BT-A (Dysport) was given in an open left-versus-right side trial with each patient being his own control for initial efficacy, followed by treatment of the contralateral side. Results: Seven days after initial treatment sweat production fell to below 10% of the untreated contralateral axilla as determined by gravimetry. Satisfaction was rated unanimously as “very good,” the highest of 5 rankings. No side effects such as skin irritation or muscle weakness were noted in any patient. Conclusion: Intradermal injection of BT-A is a potent and well-accepted therapeutic option in patients with recalcitrant axillary hyperhidrosis. (J Am Acad Dermatol 1999;41:987-90.)

The full text of this article is available in PDF format.

 Supported by a grant from an investigator-initiated study from the Departments of Dermatology and Neurology.
 Reprint requests: Marc Heckmann, MD, Dermatologische Klinik, Frauenlobstr 9-11, 80337, Munich, Germany. E-mail:
 0190-9622/99/$8.00 + 0  16/1/101082

© 1999  American Academy of Dermatology, Inc. Published by Elsevier Masson SAS@@#104157@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline